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In this study, chlorogenic acid (CGA), a phenolic compound widely distributed in fruits and
vegetables, was encapsulated into chitosan nanoparticles by ionic gelation method. The
particles exhibited the size and zeta potential of 210 nm and 33 mV respectively. A regular,
spherical shaped distribution of nanoparticles was observed through scanning electron
microscopy (SEM) and the success of entrapment was confirmed by FTIR analysis. The
encapsulation efficiency of CGA was at about 59% with the loading efficiency of 5.2%.
In vitro ABTS assay indicated that the radical scavenging activity of CAG was retained in the
nanostructure and further, the release kinetics study revealed the burst release of 69% CGA
from nanoparticles at the end of 100th hours. Pharmacokinetic analysis in rats showed a
lower level of Cmax, longer Tmax, longer MRT, larger AUC0et and AUC0e∞ for the CGA
nanoparticles compared to free CGA. Collectively, these results suggest that the syn-
thesised nanoparticle with sustained release property can therefore ease the fortification
of food-matrices targeted for health benefits through effective delivery of CGA in body.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Chlorogenic acid (CGA) is a polyphenolic antioxidant distrib-
uted widely in fruits like apple, pears, berries, plum and veg-
etables like sweet potato, lettuce, spinach, coffee beans, tea,
etc. [1,2]. Structurally, it is the esters of certain trans-cinnamic
acids (caffeic, ferulic and p-coumaric acids) and quinic acid [3].nosciences Division, Def
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form of CGA in plants. The antioxidant property of CGA is
attributed to its double bond conjugated catechol structure of
the phenyl ring. Green coffee is remarkably the richest sources
of CGAwith the content of 4e14% [4]. Several recent reports on
cell lines and animal studies have shown its pharmacological
properties that include anti-obese [5], anti-inflammatory [6,7],
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properties, and also for treating Alzheimer's disease [14] etc.
Furthermore, CGA inhibit oxidation of LDL and therefore
protect against cardiovascular diseases.
There is a growing interest in the dietary supplementation
of CGA as a nutraceutical agent in food formulations due to its
various medicinal properties. Despite its safety and effective-
ness the use of CGA is limited by its low bioavailability and
stability [15,16]. In intestine, the CGA either absorbed as an
intact form or hydrolysed forms of caffeic acid and quinic acid.
After ingestion, only a one third of CGA absorbed from
gastrointestinal tract reaches blood circulation [17]. Moreover,
CGA can also undergo enzymatic oxidation in many food pro-
cesses to quinines by polyphenol oxidase and while roasting of
green coffee beans it forms CGAs lactones and shikimates by
dehydration process [18]. Recently it was reported that the
thermal processing of foods containing a high concentration
CGA facilitate the formation of acrylamide [19]. Other oxidative
process in foods may also result in the formation of a reactive
electrophilic chlorogenoquinone, and can also undergo trans-
esterification reaction during storage/processing of foods [20].
Therefore, as an effective strategy to overcome such problems,
CGA can be encapsulated in a variety of polymers [21].
Encapsulation technique has emerged as a promising de-
livery system in the recent past and has successfully been
applied for a number of pharma drugs [22]. In food industries,
it is being targeted to improve poorly soluble and bioavailabile
phytocompounds. Also the targetability, slow release property
and stability of the substances can be greatly modified [23].
Upon ingestion, the nanoparticles in the fortified foods get
adhered to the mucosa of GIT which is a prerequisite before
transit into the body, and then transported via circulation to
different organs. Such system could prolong the therapeutic
effect of nutraceuticals at their specific target sites [24]. For
such entrapment purposes, polymers such as proteins, lipids,
carbohydrates can serve as a wall material/carrier material
depending on the nature of substances to be encapsulated.
Chitosan is one of thewidely used cationic polysacchrides due
to its nontoxicity, biocompatibility, biodegradability with
permeation enhancing properties [25,26].
The objective of the present study was to prepare and
characterize the chlorogenic acid loaded chitosan nano-
particles with preserved antioxidant activity, controlled
release property and enhanced bioavailability.
2. Materials and methods
2.1. Chemicals
Chitosanwith a deacetylation degree of 86.6% (catalogno. LMW
448869), sodium tripolyphosphate, chlorogenic acid, and 2,2-
azinobis(3-ethylbenzothiazoline-6-sulfonic acid) were pur-
chased fromSigmaAldrichChemical Co.Acetic acid,methanol,
formic acidwerepurchased fromLobaChemie,Mumbai (India).
2.2. Preparation of chlorogenic acid loaded chitosan
nanoparticles (CNP)
The nanoparticles were prepared according to the procedure
reported by Calvo et al. [27], based on the ionic gelation ofchitosan with TPP anions. In brief, chitosan was dissolved in
acetic acid aqueous solution at various concentrations and the
concentration of acetic acid in aqueous solution was, in all
cases 1.75 times that of chitosan. Under magnetic stirring at
room temperature, 3 ml of TPP aqueous solution at various
concentrations was added into 5 ml of chitosan solutions
using a peristaltic HPLC pump (Neulab, India) with 0.2 ml/min
flow rate. The final concentration of chitosan and TPP in
nanoparticle suspensions were 1.5, 2, 2.5, 3 mg/ml and 0.5, 0.6
and 0.7mg/ml respectively. The concentration of acetic acid in
aqueous solution was 1.75 times the final concentration of
chitosan. Nanoparticles were separated by centrifugation
followed by lyophilisation of nanoparticles and stored at 4 C
until further use.
2.3. Characterization of nanoparticles
2.3.1. Particle size and zeta potential
The sizes and zeta potential of the CNP were measured with a
Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Mal-
vern, U.K.). The particle size distribution of the nanoparticles
is reported as a polydispersity index (PDI). All measurements
were performed in triplicates. 3 ml of sample was taken in a
cuvette and was analysed at 25 C with at an angle of 90.
2.3.2. Scanning electron microscope (SEM)
Particle morphology was examined by scanning electron mi-
croscope (SEM) (Hitachi). The CNP were separated by centri-
fugation at 40,000 g for 30 min. The supernatant was decanted
and the pellet was freeze dried with the lyophilizer (LSI, India)
and was examined by SEM at an accelerating voltage of
15.0 kV. One drop of nanoparticles was placed on a graphite
surface and when the sample had dried then it was coated
with gold using ion sputter.
2.3.3. FTIR and DSC
FTIR spectra of chitosan, chlorogenic acid, sodium tripoly-
phosphate and CNP were obtained to detect the functional
groups using FTIR spectrometer (Thermoelectron Corpora-
tion, USA). The samples were ground finely with potassium
bromide and were then pressed mechanically to form a
translucent disc. These samples were scanned from 4000 to
400 cm1 wave number.
Differential scanning calorimetry (DSC, TA Instruments)
monitors heat effects associated with phase transitions and
chemical reactions as a function of temperature. The differ-
ence in heat flow to the sample and a reference was recorded.
DSC was calibrated using an empty aluminium pan as a
standard and samples weighing about 3e6 mg were heated in
sealed aluminium pans. Thermogram was recorded covering
a range of 25e300 C at a heat rate of 10 C/min, under dry
nitrogen condition.
2.4. Encapsulation (EE) and loading efficiency (LE)
The EE of CGA was determined by the separation of nano-
particles from the aqueousmedium containing non-associated
chlorogenic acid using ultracentrifugation at 40,000 g, 4 C for
30min. The amount of free chlorogenic acid in the supernatant
was measured by high performance liquid chromatography
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 0 3e2 1 1 205(JASCO Pu-1580 HPLC System). A 250  4.6 mm column (C18
column; Waters) was used as a solid phase. The mobile phase
consisted of 40% methanol and 0.06% formic acid. The system
was run isocratically with a flow rate of 0.8 ml/min 20 ml of
sample was injected into the column and the quantification
was done at 327 nm using Photo diode array detector (BORWIN
software). All measurements were performed in triplicate. The
encapsulation efficiency (EE) and Loading capacity (LC) of CGA
were calculated as below.
EE (%) ¼ (weight of CGA in nanoparticles  100)/weight of total
CGA
LC (%) ¼ (weight of CGA in nanoparticle  100)/weight of
nanoparticles CGA
2.5. Effect of pH on nanoparticles
pH is the one of the most important factor that affects zeta
potential and size of the nanoparticle. To evidence these
changes, pH titration was done using DLS (Malvern Zetasizer
Nano ZS) and the change in pH was plotted as a function of
size and zeta potential. The nanoparticles were autotitrated
using 0.1 N NaOH in order to find out the isoelectric point of
the sample up to pH 10.
2.6. In vitro antioxidant assay
ABTS is a free radical which oxidises the antioxidants. It is a
coloured reagent (bluish green) and when the antioxidant is
added it turns colourless. The intensity of the colour change is
measured as the function of antioxidant activity [28]. The anti-
oxidant activity of encapsulatedchlorogenic acidwas evaluated
by the 2, 2-azinobis (3-ethylbenzothiazoline-6-sulfonic acid)
ABTS radical scavenging assay. 140 mM/L ABTS stock solution
was diluted in water to 14 mM concentration. 500 ml of 14 mm
ABTS dilution and 500 ml of 4.9 mM potassium persulfate stock
solutionweremixed ina 1.5ml tube and then left to stand in the
dark and at room temperature for at least 12 h. The ABTS was
then diluted with sample buffer to an absorbance of 0.700 at
734 nm before use. After the addition of 900 ml of diluted ABTS
solution to 100 ml sample, the absorbance of sample (Asample)
was taken exactly after 6 min, and the absorbance of sample
buffer blank (Acontrol) was run in each assay. The absorbance at
734 nm was recorded by means of UV-Vis spectrometry (Shi-
madzu, Japan). All determination was carried in triplicates. IC50
of the antioxidant was calculated. The radical scavenging ac-
tivity (RSA) was calculated using the equation;
RSA (%) ¼ [(Acontrol  Asample)/Acontrol]  100
2.7. In vitro release kinetics
50 mg of nanoparticles separated by ultracentrifugation was
dissolved in 3 ml of phosphate buffer saline (pH 7.4) and 0.1 M
HCl. This was placed in a dialysis membrane with a molecular
cut off range of 7 kDa (Cat no: 68700, Pierce Make) at 37 C. Thesample containing dialysis tube was immersed in 75 ml of
phosphatebufferundermagnetic stirringcondition for 100h.At
regular intervals of time, 2 ml of the released sample was
removed and replaced with 2 ml of buffer. The amount of
chlorogenic acid in the releasemediumwasquantifiedbyHPLC.
2.8. In vivo pharmacokinetics
Wistar male (120 g) rats were kept in an environmentally
controlled animal facility operating on a 12 h dark/light cycle at
24 C and 55% humidity. 18 rats were randomly divided into
two groups (9 animals each) and they were fasted for 14e15 h
prior to CGA administration. Control group was orally admin-
istered with 100 mg/kg of free CGA and the treatment group
was given an equivalent dose of nanoparticles. Blood was
collected from bleeding of tail vein at 0.5, 1, 2, 3, 4, 5, 6, 12 and
24 h following oral administration. CGA was determined by
high performance liquid chromatography (HPLC) after extrac-
tion from the blood plasma. Briefly, to 50 ml of plasma 50 ml of
enzyme solution containing 500 U of b-glucuronidase and 25 U
of sulfatase was added and incubated at 37 C for 50min and to
this 900 ml of methanol/acetic acid (100:5, v/v) were added. The
mixture was vortexed for 30 s, sonicated for 30 s, again vor-
texed for 30 s, and centrifuged for 5 min at 4 C and 5000 g. The
supernatant was diluted with water (1:1 v/v), and 20 ml was
injected onto an HPLC column for quantification.
Pharmacokinetics parameters were determined by non-
compartmental analysis using phoenix software, Certara.
The data were presented for area under the curve (AUC), peak
concentration (Cmax), time of peak concentration (Tmax), and
mean residence time (MRT).
2.9. Thermal and storage stability
For the thermal stability studies, 3 ml of nanoparticles solu-
tion was transferred into 9 test tubes. Three test tubes were
heated for 5, 10 and 15 min at 80, 100 and 120 C respectively.
The change in the physicochemical properties of the chloro-
genic acid loaded nanoparticles after heat treatment was done
by measuring the particle size and zeta potential [29]. For
storage stability studies, three test tubes were filled with 5 ml
of the nanoparticle solution and were stored at room tem-
perature for one month. The stability of the nanoparticle was
done by measuring the size using DLS.
2.10. Statistical analysis
Results from replicates were expressed as mean ± standard
deviation. Analysis of variance was performed using the t-
test. The p values less than 0.05 were considered as significant
different.3. Results and discussion
3.1. Preparation and characterisation of CGA
nanoparticles
Chitosan is one of the widely used encapsulating agent and
several reports on chitosan based encapsulation have been
Fig. 1 e Size of the nanoparticles at various concentrations
of chitosan and TPP.
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quercetin [30], gallic acid [31], catechin and epigallocatechin
gallate [32], procyanidins [33], ferulic acid [34] and tea poly-
phenols [35]. In our study, chlorogenic acid was encapsulated
into this polymer by ionic gelation method. The effect of
various concentrations of chitosan and TPP on nanoparticle
size was evaluated. Results indicated that the mean size of
nanoparticles increased with an increase in concentration of
chitosan from 1 to 5 mg/ml with a linear relationship (Fig. 1).
The lowest mean diameter of 210 nm size was obtained at a
chitosan concentration of 1.0 mg/ml and a TPP concentration
of 0.7 mg/ml. The ratio of chitosan/TPP was 1.5:1 and this is an
important critical fabricating parameters in encapsulation.
The size distribution profile of the nanoparticles for the lowest
concentration is presented in Fig. 2. The particle size of the
chitosan nanoparticle for the catechin [36] and sylicylic acid
[37] was reported to be 130 ± 5 nm and 150e370 nm respec-
tively. The zeta potential of nanoparticle was positively
charged at about 33 mV (Fig. 3). In general, particle charge is a
stability determining factor and a zeta potential of >þ30 mV
and <30 mV is ideal for a physical stability of any suspen-
sion. When chitosan and TPP were mixed in acetic acid solu-
tion, they spontaneously formed compact nanocomplexes
with an overall positive surface charge, and the density of the
surface charge was reflected in the measured zeta potentialFig. 2 e Particle size distribution of CGA loaded chitosan nanop
concentration.values. It was also observed that zeta potential increased
linearly with increasing chitosan concentration. A similar
range of zeta potentials (>þ30 mV) have been obtained for
salicylic acid and gentamicin-loaded nanoparticles in earlier
published reports [38].
At lowest concentration of CGA (0.1 mg/ml), the encapsu-
lation efficiency (EE) was 59% with the particle size of 210 nm.
As the concentration increased to 0.5 mg/ml, the EE was
reduced to 45% and the mean particle size was increased to
255 nm (Table 1).
3.1.1. SEM and FT-IR analysis
The morphology and size distribution of the prepared nano-
particles were examined under scanning electronmicroscope.
The shape of the nanoparticles was found to be spherical,
homogeneous in shapes with smooth surface (Fig. 4). The
dimension of the nanoparticle was ~250 nm suggesting
nanodimension of the encapsulated CGA. These nanosized
particles are likely to improve CGA bioavailability through
higher absorption in body.
The FTIR spectra of nanoparticle and their ingredients are
presented in Fig. 5. Absorption in this infrared region is due to
changes in vibrational energy. The essential requirement for a
substance to absorb in these regions is that the vibrations in
the molecule must give rise to an unsymmetrical charge dis-
tribution. The region 1400e650 cm1 is known as the finger
print region and therefore this region usually checked for
identification of functional groups. It is also associated with
vibrational (and rotational) energy changes of the molecular
skeleton, and so is a characteristic of the compound under
study.
The characteristic absorption peak of chitosan was
observed at 3000e3500 cm1 (OH, NH2) [39]. The peak for
asymmetric stretch of CeOeC is found at around
1150 cm1and CH stretching at 2874 cm1. The peak at
1317 cme1 belongs to the CeN stretching vibration of type Ⅰ
amine. The peaks for NeH bending vibration of amine Ⅰ at 1589
cm1 and the amide Ⅱ carbonyl stretch at 1650 cm1 in
nanoparticles shifted to 1629 cm1 and 1529 cm1, respec-
tively. The crosslinked chitosan also show a P]O peak at
1151.1 cm1. These results can be attributed to the linkage
between phosphoric group of TPP and ammonium group of
chitosan in nanoparticles.article at 1 mg/ml of chitosan and 0.7 mg/ml of TPP
Fig. 3 e Zeta potential distribution of CGA loaded chitosan nanoparticle at 1 mg/ml of chitosan and 0.7 mg/ml of TPP
concentration.
Table 1 e Effect of various concentration of chlorogenic acid on particle size and zeta potential of the nanoparticles at the
chitosan concentration of 1 mg/ml and TPP concentration of 0.7 mg/ml. All data are mean ± SD of triplicate.
Chlorogenic acid (mg/ml) Particle size (nm) Polydispersity index Zeta potential (mV) Encapsulation efficiency (%)
0.1 210 ± 8.0 0.35 33 ± 0.9 59 ± 0.2
0.2 225 ± 9.5 0.32 34 ± 0.6 51 ± 0.3
0.3 250 ± 7.5 0.23 30 ± 0.5 48 ± 0.1
0.4 146 ± 5.0 0.43 29 ± 0.7 50 ± 0.5
0.5 255 ± 10.1 0.41 27 ± 0.6 45 ± 0.3
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 0 3e2 1 1 207The broad absorption band at 3314.8 is attributed to the
OeH vibration, 1686 to the mixed esters and carboxyl CeO vi-
bration, 1638, 1600, 1516, 1442 to the aromatic ring stretch vi-
bration, 1288, 1181, to the carboxylic CeOeC vibration. These
results are in consistent with earlier report of Wei et al., [40].
3.1.2. DSC study
DSC analysis is used as a tool to confirm the crystal trans-
formation of the nanoparticles. The DSC curves of TPP, CGA,
Chitosan and nanoparticles are shown in Fig. 6. TPP and CGA
give rise to a sharp peak at 207 C and 205 C respectively
corresponding to the melting point of crystalline region. The
chitosan polymer showed a peak at 191.6 C and nanoparticles
at 200 C. A shift in the melting point may be due to theFig. 4 e SEM image of CGA loaded chitosan nanoparticles.interaction of chitosanwith chlorogenic acid. Since the shift is
not too far, it can be assumed that the encapsulation process
did not affect the structure and properties of chitosan
polymer.
3.2. Encapsulation efficiency and loading efficiency
The encapsulation (EE) and loading capacity (LC) of the
chlorogenic acid were determined by HPLC method with the
retention time of 20.0 min. EE and LC were found to be 59 and
5.2% respectively. These are the important parameters as far
as the delivery of any nureaceuticals/drug is concerned. Pre-
vious studies have shown that encapsulation efficiency is
greatly influenced by the molecular weight of chitosan used
[41]. Depending upon the drug polymer interaction the EE can
vary on an average from 10% to 65% or more and in case of
gemcitabine-loaded chitosan nanoparticle the EE was re-
ported to be 63% [42]. The loading ability of CGA into the
nanoparticles may involve mechanism like electrostatic
interaction, encapsulation and adsorption.
3.3. Effect of pH on nanoparticle
Fig. 7 shows the titration graph of the nanoparticle from acidic
(pH 4) to alkaline (pH 10). When the pH of the suspension
increased by incremental addition of NaOH the zeta potential
of the nanoparticle steeply decreased from þ30 mV to 5 mV
and the size drastically increased from 170 nm to 1800 nm.
The change in zeta potential may be due to the addition of
alkali, and therefore the particles tend to acquire more nega-
tive charges. In titration, a point will be reached where the
Fig. 5 e FTIR spectra of chlorogenic acid, TPP, chitosan and nanoparticles.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 0 3e2 1 1208positive charge is completely neutralised by the negative
charges. This point is known as the isoelectric point (Pi) which
is defined as the pH at which the net charge of the particle is
zero and is very important from a practical consideration. Pi of
the nanoparticle was found to be at pH 7.66 indicating the
least stability of these nanoparticles at this point.Fig. 6 e DSC thermogram of TPP, CG3.4. In vitro antioxidant assay
ABTS radical cation decolorization assay is a widely used
method for the assessment of the antioxidant activity of
various substances. The IC50 value of any antioxidant refers to
the minimum amount of the substances that is required toA, chitosan and nanoparticles.
Fig. 7 e Effect of pH on particle size and zeta potential of the chitosan nanoparticles.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 0 3e2 1 1 209scavenge 50% of the radicals generated through in vitro sys-
tem. The scavenging activity of the encapsulated antioxidant
expressed in terms of percentage of radical scavenging ac-
tivity increased with increasing concentration of nano-
particles. The IC50 value of the encapsulated CGA (92 ± 5 mg/
ml) was comparable to that of an equivalent amount unen-
capsulated CGA (89 ± 3 mg/ml) indicating that sustained free
radical scavenging activity of CGA was retained in the syn-
thesised nanoparticles. Amorim et al. [43], earlier reported a
similar preserved antioxidant activity for idebenone-loaded
nanoparticles.3.5. Release kinetics in vitro
The release profile of CGA from nanoparticles was investi-
gated at 37 C over a period of 100 h (Fig. 8). 0.1 M HCl and PBS
were used to simulate the stomach and intestine conditions
respectively. The release of CGA was rapid in PBS than that of
HCl in the same period of time. It also showed a controlled
release pattern characterized by a fast initial release (25%)
during the first 10 h, followed by slower and continuous
release (69%) till 100 h. This kind of continuous and slow
release has been reported earlier for drugs such as acetylsa-
licylic acid, probucol [44]. The releasemechanism of drugmayFig. 8 e In vitro release kinetics of CGA from nanoparticles
in 0.1 M HCl and 0.1 M Phosphate buffer saline (PBS).involve either by drug molecules diffusion or by polymer
matrix degradation per se [45]. The initial burst release of drug
results from those drug molecules dispersing close to the
nanoparticle surface. Since the size of CGA is much smaller
than that of the nanoparticles, it can diffuse easily through the
surface or pores of nanoparticles quickly. Due to the hydro-
philic nature of chitosan, the release medium can easily
penetrates into the particle and dissolves the entrapped CGA
to outside. Hu et al. [46], studied and shown the controlled
release profile of entrapped tea catechins in CS-TPP
nanoparticles.3.6. In vivo pharmacokinetics analysis
Themean plasma concentrationetime curve after single-dose
administration of CGA in rats is presented in Fig. 9 and the
relevant pharmacokinetic parameters are listed in Table 2.
Encapsulated CGA had significantly lower level of Cmax, longer
Tmax, longer MRT, larger AUC0et and AUC0e∞ than that of free
CGA (p < 0.01). These results indicated that encapsulated CGA
had the slower and sustained release of CGA over longer
duration, and therefore the bioavailability is more upon oral
administration.Fig. 9 eMean plasma concentration e time curve of CGA in
control and treatment group after single oral
administration in rats (mean ± SD, 100 mg/kg, n ¼ 9).
Table 2 e The in vivo pharmacokinetic parameters of free
CGA (control) and encapsulated CGA (treated) after single
oral administration in rats (mean ± SD, n ¼ 9).
Parameters (units) Control group Treated group
Tmax (h) 1.5 ± 0.3 4.0 ± 0.5
Cmax (mg/ml) 8.07 ± 0.97 4.97 ± 0.86
MRT (h) 2.32 ± 0.7 5.38 ± 0.9
AUC0et (mg.h/ml) 12.74 ± 2.5 21.07 ± 3.4
a
AUC0e∞ (mg.h/ml) 13.14 ± 2.9 21.01 ± 4.1
a
a P < 0.01 versus control group.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 0 3e2 1 12103.7. Thermal and storage stability
The change in size and zeta potential of nanoparticles during
heat treatment at 80, 100 and 120 C is shown in Fig. 10a and b.
There was a rapid reduction in the size and zeta potential of
the nanoparticles during the initial 5 min of heating at all the
temperatures and then later up to 15 min period of time the
effect was minimal with gradual reduction on size and zeta.
Heat treatment might have affected the adsorption of
chlorogenic acid onto the surface as well as the cross-linking
structure related to the formation of the layer. As a result,
particle size was reduced and the positive charge on the sur-
face was also changed which in turn might have caused
lowering of the zeta potential. This mechanism proceeds
relatively rapidly with the rise in temperature. With further
heat treatment, however, particle size and zeta potential were
maintained within a regular range, probably because the
matrix structure in which chlorogenic acid and chitosan were
combined through ionic gelation inside the particleswasmore
stable than the particle surface. The effect of heat on nano-
particles was similar to the earlier report of Jang et al. [29], for
the encapsulated vitamin-C.Fig. 10 e Effect of heat treatment at 80, 100 and 120 C on
the particle size and zeta potential of CGA nanoparticles.Further, the stability of the nanoparticle at room temper-
aturewas studied for amonth upon storage. It was found to be
almost stable with respect to particle size as well as zeta po-
tential of the particles indicating the overall stability of the
nanoparticles in aqueous environment (data not shown).4. Conclusion
Encapsulation of CGA into chitosan was successfully carried
out in this study by ionic gelation method. The prepared
nanoparticles showed a controlled release profile and a pre-
served antioxidant activity under in vitro conditions. They also
showed a considerable heat stability demonstrating its usage
in various types of thermally processed foods. Nanoparticles
are well-known to transport bioactive compounds across the
mucosal barrier and therefore the synthesized nanoparticles
with increased bioavailability from the present study can be a
suitable carrier for better delivery of CGA in food and phar-
maceutical applications.
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